(Q43565795)

24 November 2017

title

Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide (English)

1 reference

hereditary hemorrhagic telangiectasia

24 November 2017

0 references

0 references

1 reference

1 reference

1

Massimo Franchini

1 reference

24 November 2017

Francesco Frattini

2

1 reference

24 November 2017

Silvia Crestani

series ordinal

3

1 reference

24 November 2017

Carlo Bonfanti

series ordinal

4

1 reference

24 November 2017

publication date

1 October 2013

1 reference

Journal of Thrombosis and Thrombolysis

24 November 2017

published in

1 reference

24 November 2017

volume

36

1 reference

24 November 2017

issue

3

1 reference

24 November 2017

page(s)

355-357

1 reference

Hereditary haemorrhagic telangiectasia.

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Hereditary haemorrhagic telangiectasia: a clinical and scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Hereditary hemorrhagic telangiectasia: from molecular biology to patient care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Treatment of recurrent epistaxis in HHT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Hereditary haemorrhagic telangiectasia: Pathophysiology, diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Long-term therapy with thalidomide in hereditary hemorrhagic telangiectasia: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0840-5

A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT)

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23143669

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23143669

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11239-012-0840-5

1 reference

24 November 2017

1 reference